Listen Now

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Matthew B. Harms, MD, associate professor of neurology, Columbia University, and medical consultant and care center director, Muscular Dystrophy Association (MDA). He spoke about the progress that the field has seen in recent years in improving the genetic understanding of amyotrophic lateral sclerosis (ALS) and the role that big data can play in care, as well as shared his perspective on the impact that advocacy efforts have had on these advances. Episode Breakdown: 2:05 – Major progress in ALS in recent years 4:35 – Key steps forward in genetic testing 7:25 – The understanding of genetics in ALS 9:20 – The role of databases in the care paradigm 11:35 – Neurology News Minute 15:25 – Advocacy's role in the last decade 18:40 – The state of clinical trials for ALS 20:40 – The pipeline of therapies and the future of treatment 24:50 – Importance of continued advocacy for ALS Check out Medical World News' Second Opinion only at medicalworldnews.com The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: National Institutes of Health Launches Phase 1 Trial to Study Epstein-Barr Virus Vaccine Eisai Completes Rolling BLA Submission for Lecanemab to Treat MCI, Alzheimer Disease FDA Approves Oral Version of Edaravone for ALS Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Jessica Ailani, MD, director, MedStar Georgetown Headache Center, and associate professor of neurology, MedStar Georgetown University Hospital. She spoke about some recent data in headache medicine that has provided evidence of the in-clinic experience and how the migraine treatment landscape has shifted, and what challenges need to be addressed to achieve the goal of developing personalized treatment regimens for patients. Episode Breakdown: 1:25 – Migraine highlights from the 2022 AAN Annual Meeting. 5:00 – Atogepant post hoc analyses showing dose-dependent weight loss. 9:25 – Rimegepant data and optimizing available treatments for quality of life. 12:50 – Current day-to-day challenges in migraine care. 15:10 – Neurology News Minute 18:50 – Progress made toward increasing migraine training and education. 22:45 – Other specialty's understanding of the migraine population. 27:35 – The importance of behavioral interventions in migraine. 32:05 – Looking ahead to the future of care. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Axsome Issued CRL for AXS-07 in Acute Migraine Treatment FDA Approves Ravulizumab for Adults With Generalized Myasthenia Gravis FDA Permits Marketing for Plaque-Detecting Diagnostic Test for Alzheimer Disease Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Yasar Torres-Yaghi, MD, director, Parkinsonism and Dementia Clinic, assistant professor of neurology, MedStar Georgetown University Hosptial, about the current state of therapeutic intervention for movement disorders, and this year's first annual Advanced Therapeutics in Movement & Related Disorders™ Congress, being put on by the PMD Alliance. Click here to register and find more information on the ATMRD Congress. Episode Breakdown: 3:15 – Background on the new ATMRD Congress. 6:20 – Rates of adoption of novel therapeutics for Parkinson disease. 9:35 – What attendees should expect from the Congress this year. 11:20 – The need for a multidisciplinary approach to movement disorders and the multidisciplinary features of the Congress. 12:35 – Neurology News Minute 16:30 – Education and understanding about the optimal utilization of advanced therapies in Parkinson disease. 19:10 – Ongoing trends and conversations in the movement disorder field. 21:30 – Closing thoughts. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: FDA Approves Boston Scientific’s STIMVIEW XT Guided Imaging Software for DBS FDA Extends Review of Vutrisiran for ATTR Amyloidosis 3 Months, Now Expected in July 2022 Higher-dose Erenumab Shows Better Prevention of Progression, Rationale Provided for Initiation at High Dose Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a number of individuals who presented data and spoke at the American Academy of Neurology Annual Meeting, on topics ranging from COVID-19's clinical presentation, overall trends in the care of patients with multiple sclerosis, the potential of regenerative medicine in traumatic brain injury, the real-world and long-term use of new therapy for Lennox-Gastaut syndrome, the optimal timing for the newest therapy in neuromyelitis optica spectrum disorder, the Axon Registry and incorporating EHR information into its data collection, and the impact of the pandemic on clinician burnout and mental health. Note: As part of AAN policy for the Annual Meeting, all individuals were asked to remain masked throughout the week, so there may be some moments of muffled noises as participants adjust or shift their masks. Those featured include (in order of appearance):  Jennifer Frontera, MD Stephen Krieger, MD Peter McAllister, MD Kelly Knupp, MD, MSCS Bruce Cree, MD, PhD, MAS Shrujal Baxi, MD, MPH Indu Subramanian, MD. Episode Breakdown: 1:50 – Jennifer Frontera, MD, on the long-term data collected on COVID-19 post-infection neurological sequelae. 9:55 – Stephen Krieger, MD, on the trends in thinking about multiple sclerosis pathogenesis and quality of life. 14:05 – Peter McAllister, MD, on the phase 2 STEMTRA trial of stem cell therapy in patients with traumatic brain injury. 16:45 – Kelly Knupp, MD, MSCS, on the long-term use of fenfluramine in Lennox-Gastaut syndrome and clinical pearls on titration. 19:00 – Bruce Cree, MD, PhD, MAS, on the effect of inebilizumab in patients with neuromyelitis optica spectrum disorder regardless of disease duration. 21:05 – Shrujal Baxi, MD, MPH, on the AAN's Axon Registry and how Verana Health is playing a role in data collection. 23:55 – Indu Subramanian, MD, on the effects of COVID-19 on physicians and clinicians and the difficulties that have challenged the field. Click here for more coverage of AAN 2022. Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we're covering the recent approvals of ganaxolone (Ztalmy; Marinus Pharmaceuticals) in cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, also known as CDD, as well as fenfluramine (Fintepla; Zogenix/UCB) in Lennox-Gastaut syndrome (LGS). Offering commentary is a pair of experts. The first is Scott Demarest, MD, MSCS, neurologist and clinical director of precision medicine, Children’s Hospital Colorado, and assistant professor of pediatrics-neurology, University of Colorado, and an investigator of the Marigold trial (NCT03572933). The second is Kelly G. Knupp, MD, MSCS, FAES, pediatric neurologist, Children's Hospital Colorado, and associate professor of pediatrics-neurology, University of Colorado, and an investigator of Study 1601 (NCT03355209). For more of NeurologyLive®'s coverage of ganaxolone's approval, head here: Ganaxolone Wins Landmark Approval for CDKL5 Deficiency Disorder. For more of NeurologyLive®'s coverage of fenfluramine's approval, head here: Fenfluramine FDA-Approved for Treatment of Lennox-Gastaut Syndrome. For more coverage of epilepsy and seizure disorders, head to NeurologyLive®'s Epilepsy clinical focus page. Episode Breakdown: 0:30 – Ganaxolone (Ztalmy; Marinus) approved for CDD 2:30 – Scott Demarest, MD, with his reaction to the approval 3:00 – Data from the Marigold study of ganaxolone 4:45 – Safety profile of ganaxolone in development 5:10 – Demarest on the landscape of care for CDD 6:20 – Clinical takeaways ahead of DEA scheduling for ganaxolone 8:40 – Fenfluramine (Fintepla; Zogenix/UCB) approved for LGS 10:55 – Kelly Knupp, MD, with her reaction to the new indication 11:30 – Efficacy data on fenfluramine in LGS 13:50 – Safety profile in LGS and Dravet syndrome 16:05 – Knupp on the potential to improve quality of life and optimal use Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder. News release. March 18, 2022. Accessed March 21, 2022. https://www.businesswire.com/news/home/20220318005282/en/Marinus-Pharmaceuticals-Announces-FDA-Approval-of-ZTALMY%C2%AE-ganaxolone-for-CDKL5-Deficiency-Disorder 2. FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS). News release. UCB. March 28, 2022. Accessed March 28, 2022. https://finance.yahoo.com/news/fintepla-fenfluramine-oral-solution-now-050000058.html

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Friedmann Paul, MD, head, Clinical Neuroimmunology Research Group, NeuroCure Clinical Research Center, and head, Clinical and Experimental Neuroimmunology, Experimental and Clinical Research Center, Charité–Universitätsmedizin Berlin. He shared his perspective on the state of care in neuromyelitis optica spectrum disorder (NMOSD), the need to raise awareness for symptomatic care and patient challenges, and the potential of novel therapeutic approaches to improve care. Episode Breakdown: 2:00 – State of diagnosis and care for NMOSD and similar disorders 6:00 – Role of NMOSD Awareness Month and advocacy efforts 8:45 – Current challenges with symptomatic management 11:20 – Multidisciplinary communication, coordination, and collaboration 13:05 – Neurology News Minute 16:45 – The potential of self-tolerization and curing NMOSD 19:05 – Nonpharmacologic approaches to care 20:40 – The need to improve physician awareness and education 22:45 – Advice for communicating the diagnosis to patients 24:45 – The need for patient advocacy groups The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Donepezil Transdermal System Wins FDA Approval to Treat Alzheimer Disease Dementia Sarepta Details Phase 3 EMBARK Study in DMD Ganaxolone Wins Landmark Approval for CDKL5 Deficiency Disorder Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Richard K. Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, and associate clinical professor, Medical University of South Carolina. He spoke to the current prevalence and impact of narcolepsy and offered insight into the link between the sleep disorder and cardiovascular health. Episode Breakdown: 1:40 – Overview of narcolepsy 5:00 – Manifestation of narcolepsy and misdiagnosis rates 8:35 – Link between cardiovascular health and narcolepsy 12:10 – Tips to improve healthier behavioral habits 16:10 – Resources for physicians Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Seema Khosla, MD, FCCP, FAASM, medical director, North Dakota Center for Sleep. She shared her insight into the American Academy of Sleep Medicine's ongoing initiative to switch to a fixed standard time year-round, as well as offered her perspective on the current state of care for sleep disorders. Episode Breakdown: 1:30 – AASM's position statement on daylight saving time 3:15 – The impact of daylight saving time on circadian rhythm 5:30 – Patient education on sleep and daylight saving 6:40 – What can be learned from similar attempts to address sleep issues 10:00 – Evidence in favor of fixed-standard time 11:45 – Neurology News Minute 14:50 – The state of sleep in the US 19:15 – Physicians' relationship with sleep education 23:20 – Importance of World Sleep Day and awareness 25:30 – Advice for inquiring about patient sleep The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Roche Announces Phase 3 SKYLINE Trial of Gantenerumab in Alzheimer Disease FDA Approves Saluda’s Evoke Spinal Cord Stimulation System for Chronic Intractable Pain IND Application Accepted for Phase 2b Trial of NOE-101 in Trigeminal Neuralgia Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Rishi MA, Ahmed O, Perez JHB, et al. Daylight saving time: an American Academy of Sleep Medicine position statement. J Clin Sleep Med. 2020;16(10):1781-1784. doi:10.5664/jcsm.8780  2. AASM calls for end of seasonal time changes ahead of “springing forward”. News release. AASM. March 9, 2022. Accessed March 10, 2022. https://aasm.org/aasm-calls-for-end-of-seasonal-time-changes-ahead-of-springing-forward/

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Konstantin Karmazin, MD, clinical neurologist, and chief medical officer, Prime PD. He discussed the virtual wellness studio that was recently launched, its capabilities and goals for the community of patients with Parkinson disease, and its benefits for physicians.  Episode Breakdown: 1:25 – Background on Prime PD 5:00 – The digital wellness studio's programs for PD 9:20 – Future aims for additional disease states 12:00 – Neurology News Minute 14:20 – Potential to incorporate advanced practice clinicians and specialists 17:15 – Feedback from patients and physicians 22:30 – How physicians can get involved and/or utilize Prime PD To learn more about Prime PD, check out their website: www.primepd.com The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: High-Dose ACI-35.030 Shows Positive Phase 1b/2a Interim Data as Alzheimer Vaccine Acadia Resubmits sNDA for Pimavanserin to Treat Alzheimer Disease Psychosis Tolebrutinib Shows Favorable Long-Term Safety, Efficacy in Relapsing MS Open-Label Extension Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Dhanashri P. Miskin, MD, clinical assistant professor of neurology, Thomas Jefferson University Hospitals. She offered her insight into the role that cognitive impairment plays as a symptom of multiple sclerosis (MS), the current approach to treatment and management for patients, and what challenges remain for the field to address. Episode Breakdown: 1:25 – Background on cognitive symptoms of MS 4:25 – Prevalence of cognitive issues for patients 6:05 – Current understanding of the driving factors of cognitive issues 8:15 – Management practices and approaches to prevention 13:20 – Tips on talking to patients about preventive approaches 16:30 – Neurology News Minute 19:10 – Challenges in helping patients adjust behavioral habits 23:20 – Advances in tracking cognitive changes in MS 28:00 – Potential role of EBV infection on these processes 30:35 – Most glaring need in addressing cognitive issues in MS 33:55 – COVID's impact on MS Want to learn more about EBV and MS? Click here to register for free for an in-depth NeurologyLive®panel discussion including Scott Newsome, DO (moderator); Alberto Ascherio, DPh, MD; Anne Cross, MD; Avindra Nath, MD; and Michael Racke, MD. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: 1-Week Epworth Sleepiness Scale for Children and Adolescents Validated for Pediatric Narcolepsy Baclofen Oral Suspension Approved for Treatment of Spasticity in Multiple Sclerosis Phase 2 Study of CY6463 in Alzheimer Disease With Vascular Pathology Initiated Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Bridget A. Bagert, MD, MPH, director, Ochsner Multiple Sclerosis Center, and an investigator in the clinical study of the Epstein-Barr virus (EBV)-targeted agent, ATA188 (Atara Biotherapeutics). She offered her perspective on the recent data from Ascherio et al on the relationship between EBV and multiple sclerosis (MS) that suggest it may be a root cause of the disease, as well as background on the decades of research that have led to this point and the potential of therapies that target EBV and the B cells it infects for patients with MS. Episode Breakdown: 1:25 – Background and historical data on EBV and MS 5:15 – The role B cells play in MS and EBV infection 10:20 – The current understanding of EBV as a cause of MS 14:20 – Neurology News Minute 18:05 – Immediate research needs in this area 21:00 – The clinical community’s view of this relationship 23:45 – ATA188 as an EBV-targeted approach to MS 30:00 – Closing thoughts Want to learn more about EBV and MS? Click here to register for free for an in-depth NeurologyLive®panel discussion including Scott Newsome, DO (moderator); Alberto Ascherio, DPh, MD; Anne Cross, MD; Avindra Nath, MD; and Michael Racke, MD. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Roche Designing New Phase 2 Trial of Tominersen in Huntington Disease Risdiplam Gets Priority Review for Presymptomatic SMA in Babies Under 2 Months Diverse Enrollment, Primary End Point Announced for Phase 4 ENVISION Study of Aducanumab Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Bar-Or A, Pender MP, Hodgkinson SJ, et al. Updated open-label extension clinical data and new magnetization transfer ratio imaging data from a Phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive multiple sclerosis. Presented at ECTRIMS Congress; October 13-15, 2021; Poster P638. 2. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. Published online January 13, 2022. doi:10.1126/science.abj8222

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Anne-Maree Kelly, MD, MClinEd, FACEM, senior emergency physician, Western Health; director, Joseph Epstein Centre for Emergency Medicine Research; professorial fellow, the University of Melbourne; and adjunct professor, Australian Centre for Health Law Research, Queensland University of Technology. She shared her clinical experience treating patients with headache and migraine in the emergency department (ED), offering insight into the factors that influence patient outcomes and the vital need for consensus international guidelines for ED migraine care. Episode Breakdown: 1:35 – Topline findings of a study of migraine in the ED 4:55 –The current state of guidelines for treatment and imaging  6:50 – Take-home points for emergency physicians 10:20 – State of education on headache and migraine in emergency medicine 11:40 – Neurology News Minute 14:40 – The stakeholders for developing consensus guidelines 16:30 – Additional research that is needed 19:20 – The role of experience in managing headache disorders in the ED The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: 5-SENSE Score Validated for Seizure-Onset Zone Identification, May Improve Patient Eligibility for Epilepsy Surgery FDA Approves Daridorexant for Insomnia Treatment CMS Releases Proposed Decision for Aducanumab Coverage in Alzheimer Disease Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE Kelly AM, Kuan WS, Chu KH, et al. Epidemiology, investigation, management, and outcome of headache in emergency departments (HEAD study)–a multinational observational study. Headache. 2021;61(10):1539-1552. doi:10.1111/head.14230

Welcome to this special episode of the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In 2022 and onward, whenever the FDA makes a major decision for the field of neurology, we'll be releasing short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we're covering the recent approval of daridorexant (Quviviq; Idorsia) for the treatment of insomnia. Offering commentary is Thomas Roth, PhD, director, Sleep Disorders and Research Center, Henry Ford Hospital; professor of psychiatry, Wayne State University School of Medicine; and clinical professor of psychiatry, University of Michigan College of Medicine; and an investigator in the clinical development studies. For more of NeurologyLive®'s coverage of daridorexant's approval, head here: FDA Approves Daridorexant for Insomnia Treatment. For more coverage of sleep disorders, head to NeurologyLive®'s Sleep Medicine clinical focus page. Episode Breakdown: 0:30 – Daridorexant (Quviviq; Idorsia) approved for insomnia 2:20 – Thomas Roth, PhD, with the clinical takeaways 4:30 – Efficacy data from Study 1 and Study 2 6:10 – Thomas Roth, PhD, on the efficacy profile 8:20 – Safety data from Study 1 and Study 2 9:00 – Thomas Roth, PhD, on the safety profile Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE Idorsia receives US FDA approval of Quviviq (daridorexant) 25 and 50 mg for the treatment of adults with insomnia. News release. Idorsia. January 10, 2022. Accessed January 10, 2022. https://www.biospace.com/article/releases/idorsia-receives-us-fda-approval-of-quviviq-daridorexant-25-and-50-mg-for-the-treatment-of-adults-with-insomnia/

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Jennifer Majersik, MD, MS, chief, division of vascular neurology, and professor of neurology, University of Utah, who along with 9 other colleagues, authored a report from the American Academy of Neurology (AAN) 2019 Transforming Leaders Program on the ongoing shortage of physicians in neurology. She offered her perspective on the challenge and how it can be addressed from an individual and institutional level. Episode Breakdown: 3:40 – Overview of the shortage in neurology 5:00 – Attracting new medical students to neurology 7:05 – The role of AAN and medical organizations 9:35 – The role of the individual neurologist 11:50 – The increase in fellowship training in neurology 14:00 – The impact on patient care Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Majersik JJ, Ahmed A, Chen IA, et al. A shortage of neurologists – we must act now: A report from the AAN 2019 transforming leaders program. Neurology. Published online April 30, 2021. doi:10.1212/WNL.0000000000012111 2. AAMC Report Reinforces Mounting Physician Shortage. News release. AAMC. June 11, 2021. Accessed December 30, 2021. https://www.aamc.org/news-insights/press-releases/aamc-report-reinforces-mounting-physician-shortage

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Anton Porsteinsson, MD, director, Alzheimer's Disease Care, Research and Education Program (AD-CARE); William B. and Sheila Konar Professor of Psychiatry, School of Medicine and Dentistry, University of Rochester. He shared his perspective on the progress made in Alzheimer disease in 2021, from the first approval since 2003 to the agents moving through the pipeline and the improved understanding of AD pathology, and offered a look into what the future may hold. Episode Breakdown: 1:15 – Agents in late-stage development in Alzheimer disease 10:30 – Additional agents with promise in the pipeline 17:00 – Neurology News Minute 21:05 – The next big step forward in Alzheimer 31:10 – Learning from prior failures, improving diagnostics 45:00 – Looking back on the progress in 2021, and ahead to 2022 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: American Academy of Sleep Medicine Publishes Updated Recommendations on Referring OSA Candidates for Surgery Phase 3 Study of BXCL501 for Agitation in Alzheimer Disease Initiated FDA Accepts Ublituximab Biologics License Application for Relapsing MS Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Christina Szperka, MD, MSCE, assistant professor of neurology, and director, Pediatric Headache Program, Children's Hospital of Pennsylvania. She offered up her thoughts on the current state of clinical care and awareness of pediatric migraine and shared her insight into the changes the landscape of treatment has undergone. Episode Breakdown: 1:15 – The landscape of pediatric migraine 3:00 – Challenges in diagnosing pediatric migraine 5:00 – Parental and patient awareness of signs and symptoms 6:25 – Differences between adult and pediatric migraine 11:35 – Impact of new therapies for pediatric patients 15:00 – Neurology News Minute 17:35 – The day-to-day clinical care of pediatric migraine 20:40 – Medication adherence among children and teens with migraine 24:00 – Transitioning patients from pediatric to adult care 27:40 – Challenges in conducting pediatric migraine studies 30:40 – Biggest advances in the past year and amid COVID-19 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: AAN Issues Statement on Ethical Considerations for Aducanumab Use in Alzheimer Disease Enrollment Complete for Phase 2 Study of ATH-1017 in Moderate Alzheimer FDA Accepts sNDA, Grants Priority Review to Fenfluramine for Lennox-Gastaut Syndrome Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Karl Doghramji, MD, professor of psychiatry and human behavior; professor of neurology; and medical director, Jefferson Sleep Disorders Center, at the Vickie and Jack Farber Institute for Neuroscience of Jefferson Health. He shared his perspective on the current state of care for sleep disorders, the impact of the pandemic on sleep in the US, and some of the recent advances in therapeutics and research. Episode Breakdown: 1:15 – The role of sleep in individuals' emotional and physical lives 5:40 – Current awareness about the health effects of poor sleep 8:15 – Clinical and commercial tools to measure sleep 10:45 – Recent advances in therapeutics for sleep disorders 15:20 – Tailoring specific therapies for specific patients 17:15 – Neurology News Minute 19:45 – Narcolepsy as a model for other sleep disorders 22:20 – Patient identification and differential diagnosis 25:40 – The sleep specialist's inclusion in the comprehensive care model 28:25 – Meeting the increasing demand for sleep specialists 30:40 – Sleep's role in dementia and cognition 33:50 – The state of sleep amid the COVID-19 pandemic The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Phase 3 PHOENIX Study of AMX0035 in ALS Gets Under Way FDA Approves First Oral Solution of Topiramate to Treat Epilepsy, Migraines Robert Califf, MD, Nominated by Biden Administration as Next FDA Commissioner Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Victor Sung, MD, director, UAB Huntington's Disease Clinic, codirector, UAB School of Medicine Neuroscience Module, and director, Birmingham VAMC Deep Brain Stimulation Program. Sung detailed data on the cost of genetic testing in HD that he and colleagues presented earlier this year at the International Parkinson and Movement Disorders Society Congress (MDS 2021), and the current utilization of testing in clinical practice. Episode Breakdown: 1:45 – Background on the genetic testing process 3:50 – Findings of the study presented at MDS 2021 7:30 – Future plans to evaluate genetic testing costs 11:30 – Current utilization of genetic testing for HD 14:10 – Neurology News Minute 18:05 – Raising awareness for genetic testing  21:25 – Biggest step forward in Huntington disease 25:10 – Takeaways from MDS 2021 The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Cerezen Device Gets Breakthrough Designation in Alzheimer Disease, MCI Eli Lilly Initiates Rolling Submission for Donanemab in Early Alzheimer Disease Amylyx Submits New Drug Application for ALS Treatment AMX0035 Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCE Massey M, Orem T, Sung V. Cost of Predictive Genetic Testing for Huntington’s Disease at Centers of Excellence in the US. Presented at: MDS Congress 2021; September 17-22; Virtual. Poster 240.

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Stephen Krieger, MD, professor of neurology, Icahn School of Medicine, and staff neurologist, Corinne Goldsmith Dickinson Center for MS, Mount Sinai. Krieger discussed the development of his topographical model of MS and how it has been leveraged to this point as a clinical tool, as well as offered insight into a recently initiated effort with it that he presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which was held virtually October 13-15, 2021. More information, including the iPad app that is available, can be found here, MStopography.com. Episode Breakdown: 1:15 – Background on the topographical model and its development 6:00 – Current utilization of the model and its insight into the MS disease course thus far 11:10 – The potential for the model to impact clinical care 13:05 – Neurology News Minute 15:15 – Topographical model-informed data in early MS and ECTRIMS presentation recap 21:10 – The need for better and improved tools to measure disease progression 25:00 – The future use of the topographical model of MS and closing thoughts The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: ANVS401 Demonstrates Safety, Improves Parkinson Disease Motor Function Gantenerumab Gets Breakthrough Designation for Alzheimer Following Significant Amyloid Reduction NDA Review for FT218 in Narcolepsy Still Ongoing, FDA Announces Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Krieger SC, Cook K, De Nino S, Fletcher M. The topographical model of multiple sclerosis: A dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm. 2016;3. doi:10.1212/NXI.0000000000000279 2. Laitman BM, Cook K, Fletcher M, Krieger SC. The topographical model of MS: Empirical evaluation of the recapitulation hypothesis. Mult Scler J Exper Transl Clin. 2018;4(4). doi:10.1177/2055217318806527

Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with Gregory W. Albers, MD, director, Stanford Stroke Center, Coyote Foundation Professor of Neurology and Neurological Sciences, Stanford Medical Center; and founder, RapidAI. He shared his insight into the development and clinical use of RapidAI, a platform that leverages artificial intelligence to create enhanced, high-quality images from noncontrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion data, aiming to expedient diagnoses, treatment, and transfer decisions Episode Breakdown: 1:15 – Background on RapidAI and its development 3:30 – Findings from the pivotal DIFFUSE clinical program of the system 9:15 – Immediate future plans for RapidAI's capabilities and use 15:55 – Neurology News Minute 18:50 – RapidAI as a complement to the physician in diagnosis 22:00 – Integrating the RapidAI system across the United States 24:50 – The future use of AI in stroke and neuroimaging 28:00 – Closing thoughts The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Lecanemab Rolling Submission for Alzheimer Disease Initiated by Eisai, Biogen Fenfluramine sNDA Submitted for Lennox-Gastaut Syndrome Atogepant Approved for Episodic Migraine Prevention Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.